Stefan Böhringer

Department of Biomedical Data Sciences, Leiden University Medical Center, Leiden, The Netherlands, Netherlands

Poster(s):

• (BSPOT43) Real-world overall survival after alternative dosing for pembrolizumab in the treatment of non-small cell lung cancer: a nationwide retrospective cohort study with a non-inferiority primary objective.
  Tuesday, August 27, 2024

  8:00 AM – 6:00 PM CEST